Cardiovascular Research · 2007 · 149 citations · 54 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyInflammationArrhythmia PharmacotherapyAtrial FibrillationCardiac MedicationsCardiovascular DiseaseHeart FailureReactive Oxygen SpeciesAtrial Fibrillation MechanismsAtrial Fibrillation PathophysiologyAtrial Structural RemodelingHeart Failure Molecular MechanismsHeart Failure PharmacologyOxidative Stress In Cardiovascular DiseasePeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated Receptors
BACKGROUND: Congestive heart failure (CHF) is a common cause of atrial fibrillation (AF). Oxidative stress and inflammation (profibrotic) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha, antifibrotic) factors may be involved in CHF-related remodeling. We evaluated the effects of simvastatin (antioxidant, anti-inflammatory) and fenofibrate (PPAR-alpha activator) on CHF-related atrial remodeling. METHODS AND RESULTS: Dogs were subjected to 2-week ventricular tachypacing (VTP) in the absence and presence of simvastatin (20 or 80 mg/day) or fenofibrate. Induced AF duration (DAF) was increased by VTP from 36+/-14 (non-paced controls) to 1005+/-257 s (p<0.01). Simvastatin prevented VTP-induced DAF increases (147+/-37 and 84+/-37 s at 20 and 80 mg/day, respectively), but fenofibrate did not (1018+/-352 s). Simvastatin also attenuated CHF-induced conduction abnormalities (heterogeneity-index reduced from 1.5+/-0.1 to 1.1+/-0.1 and 1.0+/-0.1 at 20 and 80 mg/day, p<0.01) and atrial fibrosis (from 19.4+/-1.3% to 10.8+/-0.8% and 9.9+/-0.8% at 20 and 80 mg/day, p<0.01), while fenofibrate did not. Simvastatin (but not fenofibrate) also attenuated VTP-induced left-ventricular nitric-oxide synthase and nitrotyrosine increases, along with hemodynamic dysfunction. Atrial fibroblast proliferation increased with 24-h fetal bovine serum (FBS) stimulation from 654+/-153 to 7264+/-1636 DPM (p<0.001). Simvastatin, but not fenofibrate, suppressed fibroblast proliferation (664+/-192 DPM, p<0.001). Simvastatin also significantly attenuated transforming growth factor-beta1-stimulated alpha-smooth muscle actin (alpha-SMA) expression (indicating myofibroblast differentiation) from 1.3+/-0.1 to 1.0+/-0.1 times baseline (p<0.05). CONCLUSIONS: CHF-induced atrial structural remodeling and AF promotion are attenuated by simvastatin, but not fenofibrate. Statin-induced inhibition of profibrotic atrial fibroblast responses and attenuation of left-ventricular dysfunction may contribute to preventing the CHF-induced fibrotic AF substrate.
54
Inflammation as a Risk Factor for Atrial Fibrillation
Ronnier J. Aviles, David O. Martin, Carolyn Apperson-Hansen et al. · Circulation · 2003 · 1.4K citations
The PPARα–leukotriene B4 pathway to inflammation control
Pallavi R. Devchand, H. J. Keller, Jeffrey M. Peters et al. · Nature · 1996 · 1.4K citations
Promotion of Atrial Fibrillation by Heart Failure in Dogs
Danshi Li, Samir Fareh, Tack Ki Leung et al. · Circulation · 1999 · 1.3K citations
Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart
Guillermo Torre‐Amione, Samir Kapadia, Joseph Lee et al. · Circulation · 1996 · 995 citations
Medicine, Cardiology, Immunology +11